Loading...
XSHG
600421
Market cap6mUSD
Jun 22, Last price  
0.24CNY
Name

Hubei Huarong Holding Co Ltd

Chart & Performance

D1W1MN
XSHG:600421 chart
P/E
P/S
0.30
EPS
Div Yield, %
Shrs. gr., 5y
-4.43%
Rev. gr., 5y
2.21%
Revenues
156m
+33.44%
226,494,00018,142,93919,130,84318,936,64214,281,20710,756,22049,188,991111,418,05944,112,97127,852,36428,177,07828,767,3081,002,70423,267,766140,188,499130,352,940125,191,437122,123,442117,170,329156,355,865
Net income
-2m
L-66.15%
15,314,9290054,812,08600119,748,05513,797,5402,169,676186,9253,210,025-8,396,587-8,930,0143,263,8199,945,242-8,863,734-6,487,066-8,279,500-4,683,815-1,585,616
CFO
-3m
L-48.62%
16,033,0460070,242,35166,210069,315,04801,966,64500006,097,9250006,016,092-5,424,399-2,787,228

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hubei Huarong Holding Co.,Ltd. is a pharmaceutical enterprise primarily engaged in the manufacturing and distribution of medicinal products across China. Its core pharmaceutical offerings notably feature Gucining Capsules and Huoxue Tongmai Capsules. Beyond its traditional drug production, the company also actively develops biological products, novel pharmaceuticals, environmental protection solutions, and agricultural goods, along with the technologies supporting these areas. The organization was formerly known as Hubei Yangfan Holding Co., Ltd. before officially adopting its current name, Hubei Huarong Holding Co.,Ltd., in November 2020. Established in 1997, the firm maintains its main operational base in Wuhan, China.
IPO date
Jun 07, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT